Eph receptors as therapeutic targets in glioblastoma

Identification of Cell Surface Targets through Meta-analysis of Microarray Data

(2015) Henry Haeberle et al.   NEOPLASIA

EphA3 Maintains Tumorigenicity and Is a Therapeutic Target in Glioblastoma Multiforme

(2013) Bryan W. Day et al.   CANCER CELL

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Therapeutic targeting of EPH receptors and their ligands

(2013) Andrew W. Boyd et al.   NATURE REVIEWS DRUG DISCOVERY

The EphA2 Receptor Drives Self-Renewal and Tumorigenicity in Stem-like Tumor-Propagating Cells from Human Glioblastomas

(2012) Elena Binda et al.   CANCER CELL

Loss of miR-204 Expression Enhances Glioma Migration and Stem Cell-like Phenotype

(2012) Z. Ying et al.   CANCER RESEARCH

Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients

(2012) Yanyang Tu et al.   Clinical & Translational Oncology

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

(2012) Christina M. Annunziata et al.   INVESTIGATIONAL NEW DRUGS

EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase

(2012) S D Wang et al.   ONCOGENE

Delta-Like Ligand 4 Correlates with Endothelial Proliferation and Vessel Maturation in Human Malignant Glioma

(2012) Zhi-Qiang Li et al.   ONKOLOGIE

EphB4 is overexpressed in gliomas and promotes the growth of glioma cells

(2012) Tao Chen et al.   TUMOR BIOLOGY

DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo

(2011) J.-L. Li et al.   CANCER RESEARCH

Role of MicroRNA-26b in Glioma Development and Its Mediated Regulation on EphA2

(2011) Ning Wu et al.   PLoS One

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma

(2010) Hideho Okada et al.   JOURNAL OF CLINICAL ONCOLOGY

Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis

(2010) Suphansa Sawamiphak et al.   NATURE

Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma

(2010) Xia Li et al.   TUMOR BIOLOGY

EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with Akt

(2009) Hui Miao et al.   CANCER CELL

Transcriptional Switch of Dormant Tumors to Fast-Growing Angiogenic Phenotype

(2009) N. Almog et al.   CANCER RESEARCH

Convection-enhanced delivery for the treatment of brain tumors

(2009) Waldemar Debinski et al.   Expert Review of Neurotherapeutics

EphrinA5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor

(2009) J-J Li et al.   ONCOGENE

Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients

(2008) Lin-Fang Wang et al.   BMC CANCER

Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity

(2008) Shinjiro Yamaguchi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Interleukin-13 Receptor  2, EphA2, and Fos-Related Antigen 1 as Molecular Denominators of High-Grade Astrocytomas and Specific Targets for Combinatorial Therapy

(2008) J. Wykosky et al.   CLINICAL CANCER RESEARCH

EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line

(2008) J. Fukai et al.   MOLECULAR CANCER THERAPEUTICS

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor

(2008) J Wykosky et al.   ONCOGENE